Cost-Effective Treatments for Irritable Bowel Syndrome.
作者信息
Shah Eric D
机构信息
Assistant Professor of Medicine Director, Gastrointestinal Motility Center Section of Gastroenterology & Hepatology Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire.
出版信息
Gastroenterol Hepatol (N Y). 2020 Jan;16(1):47-49.
Abstract
摘要
相似文献
1
Cost-Effective Treatments for Irritable Bowel Syndrome.肠易激综合征的经济有效治疗方法。
Gastroenterol Hepatol (N Y). 2020 Jan;16(1):47-49.
2
Irritable bowel syndrome: new and emerging treatments.肠易激综合征：新出现的治疗方法。
BMJ. 2015 Jun 18;350:h1622. doi: 10.1136/bmj.h1622.
3
Irritable bowel syndrome: the burden and unmet needs in Europe.肠易激综合征：欧洲的负担与未满足的需求
Dig Liver Dis. 2006 Oct;38(10):717-23. doi: 10.1016/j.dld.2006.05.009. Epub 2006 Jun 27.
4
Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome.肠易激综合征的医疗利用模式及医疗补助计划的直接医疗净费用
Curr Med Res Opin. 2003;19(8):771-80. doi: 10.1185/030079903125002540.
5
Irritable bowel syndrome in Germany. A cost of illness study.
Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1325-9. doi: 10.1097/00042737-200212000-00007.
6
Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis.肠易激综合征患者乳糜泻的血清学检测：一项成本效益分析。
Aliment Pharmacol Ther. 2004 Jun 1;19(11):1199-210. doi: 10.1111/j.1365-2036.2004.01958.x.
7
Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.电话式认知行为疗法和基于网络的认知行为疗法联合常规治疗与常规治疗对照治疗难治性肠易激综合征的 ACTIB 三臂 RCT 研究。
Health Technol Assess. 2019 Apr;23(17):1-154. doi: 10.3310/hta23170.
8
Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.草药制剂治疗肠易激综合征：一项双盲、随机、安慰剂对照、多中心试验的结果
Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9. doi: 10.1111/j.1365-2036.2004.01859.x.
9
[Alternative treatments in irritable bowel syndrome].[肠易激综合征的替代疗法]
Gastroenterol Clin Biol. 2009 Feb;33 Suppl 1:S79-83. doi: 10.1016/S0399-8320(09)71528-3.
10
Therapy of the postinfectious irritable bowel syndrome: an update.感染后肠易激综合征的治疗：最新进展
Clujul Med. 2017;90(2):133-138. doi: 10.15386/cjmed-752. Epub 2017 Apr 25.
本文引用的文献
1
Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.乳果糖呼气试验预测利福昔明治疗腹泻型肠易激综合征的疗效。
Am J Gastroenterol. 2019 Dec;114(12):1886-1893. doi: 10.14309/ajg.0000000000000444.
2
Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.利福昔明基于价值的定价增加了腹泻型肠易激综合征患者获得治疗的机会。
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2687-2695.e11. doi: 10.1016/j.cgh.2019.02.039. Epub 2019 Mar 1.
3
Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.生物标志物测试对腹泻型肠易激综合征的成本效益：支付者框架。
Clin Gastroenterol Hepatol. 2018 Sep;16(9):1434-1441.e21. doi: 10.1016/j.cgh.2018.03.025. Epub 2018 Mar 27.
4
A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.一种用于估计新型诊断性血液检测组合对腹泻型肠易激综合征诊断成本节约效果的预测模型。
Clin Ther. 2016 Jul;38(7):1638-1652.e9. doi: 10.1016/j.clinthera.2016.05.003. Epub 2016 May 31.
Zotero 插件